NEW YORK (GenomeWeb News) – Gene Network Sciences will collaborate with the University of California San Francisco Cancer Center in research focused on cancer pathways that could be used to develop therapeutics, the company said today.
The collaboration will involve using UCSF's clinical and research oncology knowledge along with GNS' REFS platform, and will continue a collaboration under which UCSF used the GNS system to discover and validate novel mediators of the cell cycle transition, which is a determinant of cancer cell proliferation and tumor growth.
The REFS technology is used to turn combinations of genetic, genomic, and clinical data into disease models for disease progression and drug response.
Under this agreement, the collaborators will continue to elucidate the RAS-MAPK and PI3K cancer pathways by building models of breast, pancreatic, and esophageal cancer based on ongoing research. The Cambridge, Mass.-based company said that these discoveries from the ongoing research will include potential novel drug targets for these cancer types.